

10/550145

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

BRUINVELS

Serial No. unknown

US National Phase of PCT/GB2004/001225

JC05 Rec'd PCT/PTO 21 SEP 2005

Atty. Ref.: 620-390

TC/A.U.: unknown

Filed: September 21, 2005

Examiner: unknown

For: 5HT2C RECEPTOR ANTAGONISTS IN THE TREATMENT OF  
SCHIZOPHRENIA

\* \* \* \* \*

September 21, 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

As suggested by 37 C.F.R. 1.97, the undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449. Copies of the International Search Report and cited references are attached.


This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:



B. J. Sadoff  
Reg. No. 36,663

BJS:alb  
901 North Glebe Road, 11th Floor  
Arlington, VA 22203-1808  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

Sheet 1 of 1

INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

620-390

SERIAL NO.

unknown

10/550145

APPLICANT

BRUINVELS

JC05 Rec'd PCT/PTO 21 SEP 2005

(Use several sheets if necessary)

FILING DATE

September 21, 2005

TC/A.U.

unknown

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,335,371 B1	01/2002	MAKI-IKOLA			

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
01/96328 A1	12/2001	WO			
0 470 039 A2	02/1992	EP			
03/091250 A1	11/2003	WO			

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	International Search Report of PCT/GB2004/001225, mailed 17 September 2004
	SODHI et al., "Epigenetic influences on the serotonin <sub>2c</sub> (5-HT <sub>2c</sub> ) receptor in psychiatric disorders", Society for Neuroscience Abstract Viewer and Itinerary Planner, Vol. 2003, Abstract No. 317.4, XP011822237
	MARCHESE et al., "Different 5-HT <sub>2A/2C</sub> antagonists impair dopamine re-uptake in the rat brain: role in catalepsy", Society for Neuroscience Abstracts, Vol. 26, No. 1-2, 2000, Abstract No. -271.13, XP00182407
	WOOD et al., "5-HT <sub>2C</sub> receptor antagonists: Potential in schizophrenia", Drug Development Research, Vol. 54, No. 2, October 2001, Pgs. 88-94, XP009032839
	DI MATTEO et al., "SB 242 084, A Selective Serotonin <sub>2C</sub> Receptor Antagonist, Increases Dopaminergic Transmission in the Mesolimbic System", Neuropharmacology, Vol. 38, No. 8, August 1999, Pgs. 1195-1205, XP000985700
	BONACCORSO et al., "SR46349-B, a 5-HT <sub>2A/2C</sub> receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens", Neuropsychopharmacology, Vol. 27, No. 3, September 2002, Pgs. 430-441, XP002288018
	KURTZ et al., "Therapy of schizophrenic patients with negative symptoms. Neuroleptic agents of the new generation", Psychopharmakotherapie, 1996, Vol. 3, No. 2, 1996, Pgs. 57-65, XP009033022
	MELTZER, "The role of serotonin in antipsychotic drug action", Neuropsychopharmacology, Vol. 21, No. 2, August 1999, Pgs. 106S-115S, XP002288019
	SCHERER et al., "Effect of a combination of flupentixol and nefazodone on negative, positive, and depressive symptoms in schizophrenic patients. Six case reports", Psychopharmakotherapie 2000, Vol. 7, No. 2, Pgs. 82-86, XP009033549
	RIEDEL et al., "Ziprasidone: A new atypical antipsychotic - Results from clinical trials", Psychopharmakotherapie 2002, Vol. 9, No. 3, Pgs. 85-94, XP009033548

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.